Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn’s Disease

Scribano, Maria Lia; Caprioli, Flavio; Michielan, Andrea; Contaldo, Antonella; Privitera, Antonino Carlo; Bozzi, R.; Calabrese, Emma; Castiglione, Fabiana; Ciccaglione, Antonio Francesco; Fave, Gianfranco Delle; Bodini, Giorgia; Costantino, Giuseppe; Horne, Robert; Saettone, Silvia; Usai, Paolo; Vernia, Piero; Fino, Sara Di; Gualberti, Giuliana; Fonzo, M. Di; Merolla, Rocco; Orlando, Ambrogio

doi:10.1016/j.dld.2018.09.026

Cited by 22 publications

(23 citation statements)

References 51 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Observational studies on HRQoL in Italian IBD patients have been extremely limited until now: 2 studies focused on differences in HRQoL following surgery [18,9] and a third study evaluated a small patient population [20]. A multinational study that included Italian patients with CD found cross-cultural variations in disease-related concerns [21].…”

Section: Discussionmentioning

confidence: 99%

“…• The 14-item TSQM explores patients' assessments of the effectiveness, side effects, and convenience of the main drug of their treatment regimen, as well as their overall satisfaction with that drug; scores range from 0 to 100 (higher scores indicate greater satisfaction) [8]. • The MARS captures the frequency of 5 types of nonadherence to the prescribed treatment; the overall index ranges from 5 to 25 (poor to optimal adherence) [9].…”

Section: Self-administered Questionnairesmentioning

confidence: 99%

“…The Rating Form of IBD Patient Concerns (RFIPC) questionnaire measures IBD-related worries [7], a major dimension of HRQoL in IBD. Compliance to lifelong treatment strategies is critical in chronic diseases: self-administered questionnaires have been developed to evaluate patients' satisfaction and adherence to therapy (Treatment Satisfaction Questionnaire for Medication −TSQM [8], and Medication Adherence Rating Scale −MARS-5-I [9]). The impact of CD on the daily working activities of patients is heavily affecting not only the patients' QoL, but also social costs: it can be assessed through the Work Productivity and Activity Impairment (WPAI), validated also in CD [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn’s disease

Armuzzi¹,

Riegler

Furfaro

et al. 2019

Digestive and Liver Disease

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Self-administered Questionnairesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn’s disease

Armuzzi¹,

Riegler

Furfaro

et al. 2019

Digestive and Liver Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…Medication adherence is measured with the Medical Adherence Report Scale (MARS-5), which has been already validated in several countries. [42][43][44] MARS-5 is a shortened and modified version of the original MARS questionnaire, which consists of five statements with respect to the patient's medical adherence in the last 1 week. 45 Patients can describe their behaviour on a 5-point Likert response scale ranging from 'always' to 'never' (1-5 points).…”

Section: Medication Adherencementioning

confidence: 99%

Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD)

et al. 2020

View full text Add to dashboard Cite

IntroductionInflammatory bowel diseases (IBD) are among the most common chronic illnesses diagnosed in childhood. Transition from paediatric to adult care is a crucial phase. The implementation of joint visits during the transition period in IBD is widely recommended, however, strong evidence supporting their benefit is still missing. In this trial, we aim to prove the superiority of joint visits compared with usual care in improving transition outcomes of adolescents with IBD.Methods and analysisThis is a randomised controlled two-arm multicentre trial. A minimum of 160 adolescents with IBD aged between 16.75 and 17 years will be recruited from Hungarian tertiary IBD centres. After randomisation, eligible subjects in the intervention arm attend a total of four joint visits with adult and paediatric gastroenterologist between the ages of 17 and 18. In the control arm, adolescents meet only the paediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologist regarding the patient’s treatment plan. Patients in both groups receive the same training and education, the only determinative difference between the two arms is the presence of the adult gastroenterologist at the joint visits. Data will be collected at inclusion, at transfer and 12 months post-transfer. Primary outcome is the change in health-related quality of life measured with the IMPACT-III questionnaire at 1 year after transfer. Secondary outcomes include the number of patients not lost to follow-up, healthcare utilisation, disease activity, medication adherence, self-efficacy, transition readiness and patient’s satisfaction. To compare the results of the two patient groups, two-sample T-test and Mann-Whitney test will be applied.Ethics and disseminationThe Scientific and Research Ethics Committee of the Hungarian Medical Research Council approved this study (50457-2/2019/EKU). Findings will be disseminated at conferences and in medical journals.Trial registration numberNCT04290156.

show abstract

“…Adherence is measured as a continuous scale, rather than dichotomous adherent/nonadherent categories, producing an ordinal instead of an interval‐scale assessment. The MARS (©Professor Rob Horne) has been validated in different languages in different clinical settings and countries and is available in 5, 9, and 10 items . All versions contain a common set of five items (MARS‐5), eg, “ I forget to take my medicines ”.…”

Section: Introductionmentioning

confidence: 99%

Portuguese version of the Medication Adherence Report Scale (MARS‐9): Validation in a population of chronic pain patients

Sampaio

Azevedo

Dias

et al. 2019

Evaluation Clinical Practice

View full text Add to dashboard Cite

Aim: The aim of present study was to perform the translation, cultural adaptation, and validation of the Medication Adherence Report Scale (MARS-P9) for the European Portuguese language in a sample of chronic pain patients. Methods: A Portuguese version of the nine-item MARS (©Professor Rob Horne) scale (MARS-P9) was constructed through a process of translation, back translation, and experts' panel evaluation. A total of 141 chronic pain patients were subsequently evaluated at four time assessments during a 1-year pain medication treatment. The protocol interview included the assessment of pain intensity and interference (BPI), clinical outcomes and quality of life (S-TOPS), and MARS-P9.Results: The internal consistency coefficient was acceptable for the total scale (α = 0.84). Exploratory factor analysis revealed a two-factor structure (intentional and unintentional nonadherence) that explained 61% of the variance. Convergent and discriminant validity were demonstrated by correlations between MARS scores and pain interference (r = 0.180, P ≤ 0.01) and S-TOPS (r = 0.242, P ≤ 0.05).Conclusion: MARS-P9 has been shown to be an adequate instrument for Portuguese researchers and clinicians to assess the pattern of adherence during the management of chronic pain. ;25:346-352. wileyonlinelibrary.com/journal/jep the provider's recommendation with respect to timing, dosing, and frequency of medication taking during the prescribed length of time. 15 Despite the effectiveness of pain medicines, they are quite often misused, with almost 50% of medication not taken as prescribed. 13 Moreover, an important recent Portuguese study that analysed the direct and indirect costs associated with chronic pain revealed a total €481.59 million of annual costs for the Portuguese population (95% CI [423.63 to 552.68]) associated with pain medicines. 16Since the WHO Adherence meeting in 2001, it is well accepted that there is no "gold standard" for measuring adherence behaviour. However, it is recognized that using questionnaires meeting basic psychometric standards, to assess specific behaviours related to specific medical recommendations, allows a better prediction of the adherence behaviour. 15 The Medication Adherence Scale (MARS) (©Professor Rob Horne), developed in England, is a feasible self-reporting scale addressing nonadherence behaviour in a nonthreatening and nonjudgmental way, which may result in truthful answers, used in a range of long-term conditions. This is a generic tool, which can be used to assess any prescribed drug regardless of the health condition. Adherence is measured as a continuous scale, rather than dichotomous adherent/nonadherent categories, producing an ordinal instead of an interval-scale assessment. The MARS (©Professor Rob Horne) has been validated in different languagesin different clinical settings and countries and is available in 5, 9, and 10 items. 17-23 All versions contain a common set of five items (MARS-5), eg, "I forget to take my medicines". In other versions, condition-specific items are adde...

show abstract

Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn’s Disease

Cited by 22 publications

References 51 publications

Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn’s disease

Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn’s disease

Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD)

Portuguese version of the Medication Adherence Report Scale (MARS‐9): Validation in a population of chronic pain patients

Contact Info

Product

Resources

About